Switch theme
Sign up to access all valuation multiples
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.
2017
46
LTM Revenue $0.9M
Last FY EBITDA -$64.0M
-$0.7M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Werewolf Therapeutics has a last 12-month revenue (LTM) of $0.9M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Werewolf Therapeutics achieved revenue of $1.9M and an EBITDA of -$64.0M.
Werewolf Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Werewolf Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $0.9M | XXX | $1.9M | XXX | XXX | XXX |
| Gross Profit | $0.9M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$64.0M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -3398% | XXX | XXX | XXX |
| EBIT | -$77.8M | XXX | -$73.6M | XXX | XXX | XXX |
| EBIT Margin | -8620% | XXX | -3904% | XXX | XXX | XXX |
| Net Profit | -$75.3M | XXX | -$70.5M | XXX | XXX | XXX |
| Net Margin | -8345% | XXX | -3741% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Werewolf Therapeutics's stock price is $1.
Werewolf Therapeutics has current market cap of $54.3M, and EV of -$0.7M.
See Werewolf Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$0.7M | $54.3M | XXX | XXX | XXX | XXX | $-1.67 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Werewolf Therapeutics has market cap of $54.3M and EV of -$0.7M.
Werewolf Therapeutics's trades at -0.4x EV/Revenue multiple, and 0.0x EV/EBITDA.
Equity research analysts estimate Werewolf Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Werewolf Therapeutics has a P/E ratio of -0.7x.
See valuation multiples for Werewolf Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $54.3M | XXX | $54.3M | XXX | XXX | XXX |
| EV (current) | -$0.7M | XXX | -$0.7M | XXX | XXX | XXX |
| EV/Revenue | -0.8x | XXX | -0.4x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 0.0x | XXX | XXX | XXX |
| EV/EBIT | 0.0x | XXX | 0.0x | XXX | XXX | XXX |
| EV/Gross Profit | -0.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | -0.7x | XXX | -0.8x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 0.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialWerewolf Therapeutics's revenue per employee in the last FY averaged $41K, while opex per employee averaged $1.6M for the same period.
Werewolf Therapeutics's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Werewolf Therapeutics's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Werewolf Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -3398% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | 52% | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $41K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.6M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 2994% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 4004% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Werewolf Therapeutics acquired XXX companies to date.
Last acquisition by Werewolf Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Werewolf Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Werewolf Therapeutics founded? | Werewolf Therapeutics was founded in 2017. |
| Where is Werewolf Therapeutics headquartered? | Werewolf Therapeutics is headquartered in United States of America. |
| How many employees does Werewolf Therapeutics have? | As of today, Werewolf Therapeutics has 46 employees. |
| Who is the CEO of Werewolf Therapeutics? | Werewolf Therapeutics's CEO is Dr. Daniel J. Hicklin,, PhD. |
| Is Werewolf Therapeutics publicy listed? | Yes, Werewolf Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Werewolf Therapeutics? | Werewolf Therapeutics trades under HOWL ticker. |
| When did Werewolf Therapeutics go public? | Werewolf Therapeutics went public in 2021. |
| Who are competitors of Werewolf Therapeutics? | Similar companies to Werewolf Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Werewolf Therapeutics? | Werewolf Therapeutics's current market cap is $54.3M |
| What is the current revenue of Werewolf Therapeutics? | Werewolf Therapeutics's last 12 months revenue is $0.9M. |
| What is the current EV/Revenue multiple of Werewolf Therapeutics? | Current revenue multiple of Werewolf Therapeutics is -0.8x. |
| Is Werewolf Therapeutics profitable? | Yes, Werewolf Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
